For lung adenocarcinoma with just EGFR 19Del mutation, the Observation group showed a better ORR and mPFS than the EGFR-TKIs alone group, but DCR and 1-year/2-year survival were not significantly different (Tables 5 and 6; Fig. 2). The gene discussed is EGFR; the disease is lung adenocarcinoma.